For all BMI/sex groups, initiating colonoscopy at 45 years or annual FIT at 40 years is cost-effective at threshold of $100,000/QALY
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
THURSDAY, Aug. 11, 2022 (HealthDay News) -- Initiating colonoscopy every 10 years (Colo10) at age 45 years or an annual fecal immunochemical test (FIT) at 40 years is cost-effective for all body mass index (BMI) and sex groups, according to a study published online Aug. 4 in Clinical Gastroenterology & Hepatology.
Aaron Yeoh, M.D., from the Stanford University School of Medicine in California, and colleagues compared colorectal cancer (CRC) screening starting at age 45 or 40 versus 50 years and/or shortening screening intervals among women and men with a body mass index (BMI) ranging from normal to grade III obesity. Screening strategies included Colo10, colonoscopy every five years (Colo5), or annual FIT.
The researchers found that sex-specific total CRC deaths were similar for persons with overweight and obesity I to III without screening, reflecting the counterbalance of increased CRC risk by lower life expectancy with increasing BMI. Colo10 starting at 45 years or FIT starting at 40 years were cost-effective at a threshold of $100,000/quality-adjusted life-year (QALY) gained for all BMI/sex groups. Among men with obesity II and III only, Colo10 starting at 40 years was cost-effective at $93,300 and $80,400/QALY gained, respectively. The preference was always for shifting Colo10 to an earlier starting age rather than Colo5 starting at later ages. In a sensitivity analysis, results were robust.
"Our findings have implications for CRC screening in obese persons specifically, as well as generalizable lessons for CRC screening tailored to risk," the authors write.
One author disclosed financial ties to the biotechnology and medical device industries.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 21, 2022
Read this Next
Other Trending Articles